Related Experiment Video
Updated: Sep 19, 2025

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility
Published on: April 21, 2022
Anticoagulation Therapy and Influence on Retinal Vein Occlusion and Intraocular Bleeding Risk Across a Large US
Matthew W Russell1,2, Priya Shukla2,3, Rishi P Singh2,4
1Cleveland Clinic Cole Eye Institute.
Background And Objective:
Management of hypercoagulable states with systemic anticoagulation is standard of care. The risk of future retinal vein occlusion (RVO) development with direct oral anticoagulation agents (DOACs) has yet to be investigated in a large United States cohort.
Patients And Methods:
Retrospective cohort study using a large ICD-10 coded database. The database was queried for patients being managed with warfarin or DOACs. Propensity score matching was then used to create comparable groups. Risk ratios for RVO and intraocular bleed development in patients without a prior diagnosis of RVO were calculated.
Results:
Patients managed with warfarin were found to be at significantly increased risk of developing a new diagnosis of all RVO (risk ratio [RR]: 1.49, 1.42-1.57), vitreous hemorrhage (RR: 2.14, 1.98-2.30), retinal hemorrhage (RR: 1.84, 1.71-1.97) and choroidal hemorrhage (RR: 2.06, 1.53-2.79), compared to patients managed with DOACs.
Conclusion:
These findings suggest DOACs are associated with significantly reduced retinal vein occlusion and intraocular bleeding risk compared to warfarin.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

